Nav: Home

The delicate balance of treating growing but brittle bones

February 01, 2019

Turning off a bone receptor protein could potentially treat osteoporosis in children without affecting bone growth.

Osteoporosis is a medical condition that causes bones to become fragile and brittle. It is a major health problem worldwide, mainly affecting adults. However, children can also rarely be affected as a result of other diseases or genetic disorders.

Adults are commonly treated for osteoporosis with drugs called bisphosphonates, which slow the activity of bone-absorbing cells called osteoclasts, allowing bone-building cells known as osteoblasts a better chance to work effectively. Since osteoclasts play an intrinsic role in the process of bone growth, there are concerns that bisphosphonates could negatively affect bone development in children. As of now, not enough research has been done to fully understand the potential consequences.

However, according to a study published in Bone, Masahiko Takahata of Hokkaido University and colleagues in Japan have found early evidence that inhibiting a bone receptor protein could help treat osteoporosis in children without impairing bone growth.

Through testing in rats, Takahata and his colleagues used an antibody to neutralize a bone receptor protein called Siglec-15. This receptor is involved in bone remodelling--the lifelong process of bone resorption and formation--and regulates bone marrow production of osteoclasts.

The team found that inhibiting Siglec-15 in the growing bones of young rats increased bone mass and strength without impairing growth. On the other hand, while normal bisphosphonate treatment also increased bone mass and strength, it caused bone abnormalities and growth retardation.

The researchers hypothesize that the anti-Siglec-15 therapy suppresses osteoclast activity in one layer of the growth plate at the end of bones, the secondary spongiosa, without affecting the osteoclasts in another growth plate layer, the primary spongiosa. This is because the primary spongiosa osteoclasts can respond to other signals for continuous generation and activation.

These findings suggest that anti-Siglec-15 therapy could be an alternative therapy with an ideal safety profile for osteoporosis in children, the researchers say; but further studies are required, as osteoclast behaviour in rats may not fully align with that in humans.

Discussing his and the team's work, Dr. Takahata remarked "to develop a novel therapy for clinical treatment of juvenile osteoporosis, we plan to verify the effect of anti-Siglec-15 therapy on bone mass, continuing to experiment with an animal model of juvenile osteoporosis in our future studies."
-end-


Hokkaido University

Related Osteoporosis Articles:

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.
A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.
Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.
Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.
A new 'atlas' of genetic influences on osteoporosis
A ground-breaking new study led by researchers from the Lady Davis Institute (LDI) at the Jewish General Hospital (JGH) has succeeded in compiling an atlas of genetic factors associated with estimated bone mineral density (BMD), one of the most clinically relevant factors in diagnosing osteoporosis.
New recommendations for the conduct of economic evaluations in osteoporosis
An expert working group has established recommendations for the design and conduct of economic evaluations in osteoporosis, as well as guidance for reporting these evaluations.
From receptor structure to new osteoporosis drugs
Researchers at the University of Zurich have determined the three-dimensional structure of a receptor that controls the release of calcium from bones.
How a Mediterranean diet could reduce osteoporosis
Eating a Mediterranean-type diet could reduce bone loss in people with osteoporosis -- according to new research from the University of East Anglia.
Osteoporosis drug may benefit heart health
The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures.
New treatment for osteoporosis provides better protection against fractures
A new treatment for osteoporosis provides major improvements in bone density and more effective protection against fractures than the current standard treatment.
More Osteoporosis News and Osteoporosis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.